Advertisement
Screener

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Increase Decrease In Operating Lease Liability

2.8 / 5 stars · 68/120 Roast Me

IOVANCE BIOTHERAPEUTICS, INC. Increase Decrease In Operating Lease Liability

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Increase Decrease In Operating Lease Liability of -$2.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06

  • IOVANCE BIOTHERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$773.00K.
  • IOVANCE BIOTHERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$2.03M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$2.90M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$2.41M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2025 was -$10.90M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2024 was -$12.07M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2023 was -$10.79M.
  • IOVANCE BIOTHERAPEUTICS, INC. increase decrease in operating lease liability for fiscal 2022 was -$1.94M.
Period endIncrease Decrease In Operating Lease Liability 3 monthIncrease Decrease In Operating Lease Liability 6 monthIncrease Decrease In Operating Lease Liability 9 monthIncrease Decrease In Operating Lease Liability 12 month
2026-06-30-$773.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$2.80M
10-Q · filed 2026-08-06
-$5.70M
derived: sum of 3 quarters · filed 2026-08-06
-$8.11M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$2.03M
10-Q · filed 2026-05-07
-$4.93M
derived: sum of 2 quarters · filed 2026-05-07
-$7.34M
derived: sum of 3 quarters · filed 2026-05-07
-$9.81M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31-$2.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$5.31M
derived: sum of 2 quarters · filed 2026-02-24
-$7.79M
derived: sum of 3 quarters · filed 2026-08-06
-$10.90M
10-K · filed 2026-02-24
2025-09-30-$2.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$4.89M
derived: sum of 2 quarters · filed 2026-08-06
-$8.00M
10-Q · filed 2025-11-06
-$11.65M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$2.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
-$5.59M
10-Q · filed 2026-08-06
-$9.24M
derived: sum of 3 quarters · filed 2026-08-06
-$12.19M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$3.11M
10-Q · filed 2026-05-07
-$6.76M
derived: sum of 2 quarters · filed 2026-05-07
-$9.71M
derived: sum of 3 quarters · filed 2026-05-07
-$12.40M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$3.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$6.60M
derived: sum of 2 quarters · filed 2026-02-24
-$9.29M
derived: sum of 3 quarters · filed 2026-02-24
-$12.07M
10-K · filed 2026-02-24
2024-09-30-$2.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$5.63M
derived: sum of 2 quarters · filed 2025-11-06
-$8.42M
10-Q · filed 2025-11-06
-$11.14M
derived: sum of 4 quarters · filed 2026-02-24
2024-06-30-$2.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$5.48M
10-Q · filed 2025-08-07
-$8.20M
derived: sum of 3 quarters · filed 2026-02-24
-$11.01M
derived: sum of 4 quarters · filed 2026-02-24
2024-03-31-$2.79M
10-Q · filed 2025-05-08
-$5.51M
derived: sum of 2 quarters · filed 2026-02-24
-$8.32M
derived: sum of 3 quarters · filed 2026-02-24
-$11.01M
derived: sum of 4 quarters · filed 2026-02-24
2023-12-31-$2.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24
-$5.53M
derived: sum of 2 quarters · filed 2026-02-24
-$8.22M
derived: sum of 3 quarters · filed 2026-02-24
-$10.79M
10-K · filed 2026-02-24
2023-09-30-$2.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$5.50M
derived: sum of 2 quarters · filed 2024-11-07
-$8.07M
10-Q · filed 2024-11-07
-$10.38M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30-$2.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$5.26M
10-Q · filed 2024-08-08
-$7.57M
derived: sum of 3 quarters · filed 2025-02-27
-$8.11M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31-$2.57M
10-Q · filed 2024-05-09
-$4.88M
derived: sum of 2 quarters · filed 2025-02-27
-$5.41M
derived: sum of 3 quarters · filed 2025-02-27
-$5.20M
derived: sum of 4 quarters · filed 2025-02-27
2022-12-31-$2.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
-$2.84M
derived: sum of 2 quarters · filed 2025-02-27
-$2.63M
derived: sum of 3 quarters · filed 2025-02-27
-$1.94M
10-K · filed 2025-02-27
2022-09-30-$536.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07
-$324.00K
derived: sum of 2 quarters · filed 2023-11-07
$366.00K
10-Q · filed 2023-11-07
-$127.00K
derived: sum of 4 quarters · filed 2024-02-28
2022-06-30$212.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$902.00K
10-Q · filed 2023-08-08
$409.00K
derived: sum of 3 quarters · filed 2024-02-28
-$2.09M
derived: sum of 4 quarters · filed 2024-02-28
2022-03-31$690.00K
10-Q · filed 2023-05-10
$197.00K
derived: sum of 2 quarters · filed 2024-02-28
-$2.30M
derived: sum of 3 quarters · filed 2024-02-28
-$3.82M
derived: sum of 4 quarters · filed 2024-02-28
2021-12-31-$493.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
-$2.99M
derived: sum of 2 quarters · filed 2024-02-28
-$4.51M
derived: sum of 3 quarters · filed 2024-02-28
-$5.88M
10-K · filed 2024-02-28
2021-09-30-$2.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
-$4.01M
derived: sum of 2 quarters · filed 2022-11-03
-$5.39M
10-Q · filed 2022-11-03
2021-06-30-$1.52M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
-$2.89M
10-Q · filed 2022-08-04
2021-03-31-$1.37M
10-Q · filed 2022-05-05
2020-12-31-$11.47M
10-K · filed 2023-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B